Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Tempus AI, Inc. (NASDAQ:TEM) have received an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $78.6154.

TEM has been the topic of a number of research analyst reports. HC Wainwright raised their target price on Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a report on Monday, March 9th. BTIG Research reduced their price objective on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Canaccord Genuity Group lowered their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a research report on Wednesday, February 25th. Finally, Morgan Stanley cut their target price on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd.

Insider Activity at Tempus AI

In related news, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the transaction, the chief executive officer directly owned 694,354 shares in the company, valued at $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the completion of the transaction, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This trade represents a 9.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 402,591 shares of company stock worth $24,868,936. Insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

Several institutional investors have recently modified their holdings of the company. GC Wealth Management RIA LLC bought a new position in Tempus AI in the fourth quarter worth $399,267,000. Vanguard Group Inc. increased its holdings in Tempus AI by 22.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after buying an additional 1,706,837 shares during the period. Voloridge Investment Management LLC raised its stake in shares of Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after buying an additional 1,039,176 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Tempus AI by 312.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after acquiring an additional 965,730 shares during the period. Finally, AQR Capital Management LLC bought a new position in shares of Tempus AI during the 2nd quarter worth about $54,020,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Trading Down 4.2%

Tempus AI stock opened at $46.76 on Thursday. Tempus AI has a 52 week low of $36.22 and a 52 week high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. The firm has a market capitalization of $8.36 billion, a PE ratio of -33.16 and a beta of 5.29. The business’s 50-day simple moving average is $56.13 and its 200-day simple moving average is $70.16.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.